[	O
Autologous	O
bone	B-Cell
marrow	I-Cell
stem	I-Cell
cell	I-Cell
or	O
peripheral	B-Cell
blood	I-Cell
endothelial	I-Cell
progenitor	I-Cell
cell	I-Cell
therapy	O
in	O
patients	O
with	O
peripheral	O
limb	B-Organism_subdivision
ischaemia	O
]	O

No	O
effective	O
medical	O
therapies	O
have	O
been	O
developed	O
sofar	O
to	O
enhance	O
blood	B-Organism_substance
flow	O
in	O
the	O
legs	B-Organism_subdivision
of	O
patients	O
with	O
peripheral	B-Multi-tissue_structure
arterial	I-Multi-tissue_structure
disease	O
(	O
PAD	O
)	O
.	O

For	O
patients	O
with	O
limb	B-Organism_subdivision
threatening	O
ischaemia	O
the	O
only	O
option	O
for	O
relief	O
of	O
rest	O
pain	O
or	O
gangraena	O
is	O
amputation	O
.	O

There	O
is	O
evidence	O
in	O
experimental	O
and	O
clinical	O
studies	O
that	O
adult	O
bone	B-Cell
marrow	I-Cell
-	I-Cell
derived	I-Cell
stem	I-Cell
cells	I-Cell
and	O
endothelial	B-Cell
progenitor	I-Cell
cells	I-Cell
participate	O
in	O
the	O
development	O
of	O
new	O
blood	B-Multi-tissue_structure
vessels	I-Multi-tissue_structure
,	O
called	O
neoangiogenesis	O
or	O
neovascularization	O
.	O

Clinical	O
results	O
induced	O
by	O
autologous	O
bone	B-Cell
marrow	I-Cell
stem	I-Cell
cells	I-Cell
or	O
angiogenic	O
growth	O
/	O
differentiation	O
factors	O
in	O
end	O
-	O
stage	O
patients	O
with	O
PAD	O
are	O
summarized	O
.	O

Considering	O
the	O
relatively	O
few	O
number	O
of	O
patients	O
treated	O
by	O
angiogenic	O
therapy	O
,	O
the	O
interpretation	O
of	O
clinical	O
results	O
needs	O
cautiousness	O
.	O

